Can a Rapid Blood Screen Distinguish Delta-8 THC, Delta-9 THC and HHC?
A high-resolution mass spectrometer does not automatically distinguish every cannabinoid isomer. In a validated whole-blood screening method, some closely related cannabinoids remained incompletely separated. That limitation matters whenever an expert assigns a specific compound name to a screening signal.
What the method established
Schirmer and colleagues expanded an LC–QTOF–MS method to cover 24 phytocannabinoids and semisynthetic cannabinoids in whole blood. This was analytical validation, not a human dosing or driving experiment. Reported detection limits varied by analyte, ranging from 0.8 to 16 ng/mL. A negative result therefore has to be interpreted against the particular compound’s detection limit and inclusion in the panel.
The separation problem
The authors report that their qualitative method did not fully resolve delta-9 THC from delta-8 THC, or the corresponding 11-hydroxy metabolites. The two HHC epimers also coeluted. Related structures can produce similar fragmentation patterns; accurate mass alone does not eliminate this problem.
That does not make the method useless. It means that broad screening and definitive assignment of a particular isomer are different analytical objectives. The laboratory should explain whether the actual result is a presumptive identification, a group-level signal, or an identification supported by additional separation.
Handling the specimen also matters
The study identified adsorption concerns for some larger, lipophilic cannabinoids during preparation and storage. Recovery, matrix effects, and detection limits are distinct characteristics. Good recovery for one compound does not establish equally good performance for all compounds in the panel.
Questions for the laboratory record
Request the target list, chromatograms, retention-time criteria, reference standards, matrix validation, and any follow-up method used to resolve overlapping compounds. Establish whether the reported specimen was whole blood rather than plasma or serum. Ask how an unresolved pair was handled in the final wording.
The study did not establish concentration-based impairment thresholds or determine the behavioral potency of every newly detected cannabinoid. A screening identification can support an exposure investigation without supplying a conclusion about driving ability, timing of use, or the cause of an incident.
Related evidence
See our related analysis of toxicology evidence and its limits.
Primary research
Rapid LC–QTOF–MS screening method for semi-synthetic cannabinoids in whole blood. Journal of Analytical Toxicology, 2025. DOI: 10.1093/jat/bkaf095.
